lue; 1,000 million shares authorized; and 562.5 million shares issued and outstanding (2010: 1,000 million shares authorized; and 562.2 million shares issued and outstanding) 55.7 55.7 Additional paid-in capital 2,824.5 2,746.4 Treasury stock: 12.5 million shares (2010: 14.0 million) (293.1) (276.1) Accumulated other comprehensive income 88.5 85.7 Retained earnings/(accumulated deficit) 279.1 (160.3) Total equity 2,954.7 2,451.4 Total liabilities and equity 6,065.6 5,387.6
Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Income
9 months 3 months to 3 months to 9 months to to September September September September 30, 30, 30, 30, 2011 2010 2011 2010 $M $M $M $M Revenues: Product sales 1,018.4 794.3 2,901.0 2,276.8 Royalties 62.8 76.5 199.8 254.5 Other revenues 4.9 3.5 20.4 8.6 Total revenues 1,086.1 874.3 3,121.2 2,539.9 Costs and expenses: Cost of product sales(1) 166.5 112.7 434.7 333.7 Research and development(1) 201.5 197.9 556.3 475.9 Selling, general and administrative(1) 452.1 392.4 1,295.3 1,106.7 Loss/(gain) on sale of product rights 0.3 - 3.8 (4.1) Reorganization costs 5.0 9.7 18.0 23.3 Integration and acquisition costs 5.3 5.8 7.9 6.4 Total operating expenses 830.7 718.5 2,316.0 1,941.9 Operating income 255.4 155.8 805.2 598.0 Interest income 0.3 1.0 1.5 1.9 Interest expense (9.7) (8.3) (28.8) (25.6) Other income, net 15.6 0.8 15.9 9.0 Total other income/(expense), net 6.2 (6.5) (11.4) (14.7) Income before income taxes and equity in earnings/(losses) of equity method investees 261.6 149.3 793.8 583.3 Income taxes (69.5) (52.7) (187.3) (160.8) Equity in earnings/(losses) of equity method investees, net of taxes 0.8 (0.3) 3.2 0.2 Net income 192.9 96.3 609.7 422.7
(1) Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.5 million f
'/>"/>
SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Related biology technology :1.
NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship2.
FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)3.
Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time4.
Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents5.
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)6.
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder7.
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging8.
Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period9.
Reportlinker Adds Shire plc: PharmaVitae Profile10.
Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease11.
Shire plc - Statement re ProAmatine